Jonathan Webster

8PUBLICATIONS
21CO-AUTHORS
Haematological tumoursAutomotive safety engineeringMedical molecular engineering of nucleic acids and proteinsMedical infection agents (incl. prions)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 15, 2026
Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

John Preston Claiborne, Hua-Ling Tsai, Gabriel Ghiaur

|Oct 17, 2024
A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B-cell or T-cell acute lymphoblastic leukemia: Results from the ECOG-ACRIN EA9152 protocol.

Neil D Palmisiano, Ju-Whei Lee, David F Claxton

|Aug 08, 2023
This CAR won't start: predicting nonresponse in ALL.

Jonathan A Webster, Leo Luznik

|Feb 06, 2023
Venetoclax in combination with hypomethylating agent for the treatment of advanced myeloproliferative neoplasms and acute myeloid leukemia with extramedullary disease.

Khaled Sanber, Kevin Ye, Hua-Ling Tsai

|Apr 05, 2022
Genomic landscape of myelodysplastic/myeloproliferative neoplasm can predict response to hypomethylating agent therapy.

Theodoros Karantanos, Hua-Ling Tsai, Lukasz P Gondek

|Jul 21, 2021
A phase II study of azacitidine in combination with granulocyte-macrophage colony-stimulating factor as maintenance treatment, after allogeneic blood or marrow transplantation in patients with poor-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Jonathan A Webster, Meera Yogarajah, Marianna Zahurak

Pageof 2

Frequent Collaborators

3 joint publications

William B Dalton

3 joint publications

Tania Jain

2 joint publications

B Douglas Smith

1 joint publications

Cristina Correia